Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 9-Month, Brain Imaging and Safety and Efficacy Study of TRx0237 in Subjects With Early Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo. In addition, an open-label, delayed-start phase is included to demonstrate a disease-modifying effect of TRx0237.
SIMR (Sacramento/Valley Area) Please contact Dawn Lenakakis at LenakaDR@sutterhealth.org about Study TauRX LUCIDITY StudyView study details on ClinicalTrials.gov
Active, Not Recruiting
April 15, 2019